Frequently Asked Questions

Olfactive Biosolutions repurposes food molecules, utilizing ectopic receptors to elicit physiological benefits comparable to drugs.

This innovative approach explores the potential of olfactory, taste and ectopic receptors in harnessing therapeutic effects of common food, beverage and fragrance ingredients.

Pivit is a line of precision-therapeutic products that comprise proprietary formulations of food, beverage or fragrance molecules.  

These formulations are designed to activate ectopic receptors in the gut and elsewhere to provide beneficial physiological effects such as GLP-1 and GIP secretion for potential weight loss and blood sugar reduction.  Other Protenx formulations correlate ingredients to receptor activity that releases neurotransmitters such as serotonin and thus potentially help to relieve anxiety or depression.

Olfactive Biosolutions sells these formulations to food and beverage and consumer packaged goods companies for inclusion in their products, such as snacks, bars, coffee and other products, and direct to consumer as supplements beginning Q22025.

"Lack of hunger"

"Feeling a lack of interest in food"

 "Indifference to food, no cravings (for sweets or alcohol or bread)"

 "Lost 3.3 lbs in 7 days"

"Subverts cravings"

 "Produces a general mellowness"

 "Needed to force myself to drink protein shakes after taking Pivit"

“Lost 15 lbs in 14 days”

“Lost 11 lbs in less than two weeks”

“Back to my high-school weight”

“Blood sugar level went down to average of around 98 mg/dL from average range of 110-123 mg/dL

“Completely turned off food noise”

“Pivit supports my fasting and helps me burn calories all the way through my fasting period”

"Uninterested in food"

"When eating, leaves sensation of being full/overfull"

"After three days lack of interest in sweets or snacking"

“Eliminated my after-dinner snacking”

Olfactive Biosolutions sells its Pivit line of proprietary health and wellness formulations to large food and beverage and consumer packaged goods companies for new product development and inclusion in existing products.  We also sell Pivit direct to consumer as supplements. We also license our technology to selected third parties.

We use natural food molecules found on the FDA-approved GRAS (Generally Recognized as Safe) list.

No, Pivit is not an FDA-approved drug. 

While Olfactive Biosolutions is developing products with therapeutic potential, they are not currently FDA-approved as drugs, but rather as ingredients for food and beverage products.

Examples of Products:

• Pivit™ Weight Loss: A line of natural food ingredients and additives targeting weight loss and blood sugar reduction.
• Pivit™ Blood Pressure: A formulation to reduce blood pressure, available as a supplement.

Olfactive Biosolutions uses proprietary formulations of food molecules to activate ectopic receptors in the body, to replace pharmaceuticals and treat myriad chronic diseases.

This approach promises the ability to bring health and wellness to large parts of the globe.  Food molecules are cheap and plentiful. We have been eating them for millennia.  Unlike pharmaceuticals, they have few side effects and can be consumed on a long-term basis.

Olfactory receptors (ORs) and taste receptors (TRs) occur in the nose and tongue and allow us to smell and taste the world, sensing up to one trillion different tastes and smells.  These same receptors occur throughout the body, where they are generally referred to as ectopic receptors.  These ectopic receptors participate in diverse biological processes, including the regulation of glucose and lipid metabolism.

Ectopic ORs and TRs can regulate a variety of metabolic events including insulin secretion, glucagon secretion, fatty acid oxidation, lipogenesis, and thermogenesis. Understanding the physiological function and deciphering the olfactory recognition code by suitable ligands make ectopic ORs and TRs potential targets for treating many different diseases.

Olfactive Biosolutions’ Pivit line of formulations are sold DTC as supplements.  They are also incorporated into food and beverage products on a royalties basis.  The company also licenses its patents and technology to supplements companies and compounding pharmacies.

Olfactive Biosolutions has developed world-leading receptor technology and expertise in both olfactory and taste receptors in the nose and tongue, and ectopic receptors in the gut, lungs, skin, heart, blood and elsewhere. 

Our TruePath platform for working with these receptors and the ligands that interact with them comprises our proprietary cell lines, DNA sequences, genes encoding required accessory and assay signaling proteins, proprietary protein expression techniques, cellular assays, liquid handling robots and our proprietary software, machine learning algorithms and receptor-trained AI. 

The platform allows us to perform rapid high-throughput screening of food, beverage and fragrance molecules against a host of receptors in different parts of the body to determine which are promising for affecting various physiological pathways.

Olfactive Biosolutions’ unique technology demonstrates how ectopic receptors often perform the same physiological tasks as active pharmaceutical ingredients (APIs), and what ligands activate or inhibit them.  These ligands can often be from foods that humans have traditionally eaten.

Our first product is Protenx Weight Loss / Blood Sugar Reduction, in many ways a better approach to weight loss and blood sugar reduction than are Ozempic and other similar drugs.

Ozempic is basically an edited version of GLP-1.  Ozempic’s maker Novo Nordisk edited it to last longer in the body than native GLP-1, to get pronounced weight loss and blood sugar effects.  The patient injects the modified GLP-1/Ozempic into his or her body.

In our case, we have the patient ingest a formulation of food molecules, through a cup of coffee or a cookie or similar product, or as a supplement.  The formulation is scientifically tuned to activate an ectopic receptor in the gut, OR51E1, which then causes the generation of natural GLP-1 (the exact step-by-step mechanism of action (MOA) and supporting data are available on request.)  This natural GLP-1 does not last as long in the body as Ozempic, but we have turned on the GLP-1 pump so as long as OR51E1 remains active the patient will have GLP-1, and will get the same effects as Ozempic but without the side effects (the edited Ozempic molecule has never been encountered by humans before, where humans have been eating the food molecules we use for centuries.) 

OR51E1 remains active as long as it has access to the appropriate food molecules in our formulation.  In time we can tune the formulation to subsist in the gut as long as we need the increased GLP-1 levels.

Essentially, we are using formulations of food molecules to cause a conformational change in the molecular structure of OR51E1. 

Activation of OR51E1 induces a glucose-induced membrane depolarization of endogenous GI cells, more particularly, L-enteroendocrine and pancreatic α-cells and, thereby, opens the voltage-dependent Ca²⁺ (VDC) channels of the L- and α-cells, and the resulting Ca²⁺ influx triggers vesicular exocytosis and increases secretion of GLP-1.

This same approach applies to GIP, so concurrent activation of both GLP-1 and GIP is possible using the corresponding ligands. 

The secreted GLP-1 binds to and activates GLP-1 receptor proteins on pancreatic cells, which induces the secretion of insulin.  The secreted insulin also binds to insulin receptors (IR) of the endogenous hepatic cells to suppress hepatic glucose output by inhibiting adipose lipolysis and, thereby, release of glucose into an individual's bloodstream.

The secreted GLP-1 also binds to and activates GLP-1 receptor proteins on endogenous GI cells whereby glucagon release is suppressed. The secreted GLP-1 also suppresses  glucagon secretion indirectly  via its insulinotropic effect  on the pancreatic cells.

The secreted insulin then binds to the insulin receptors (IR) of endogenous cells to effectuate the activation of cell signaling cascades that modulate energy metabolism and decrease blood glucose.

We have extensive proprietary data from thousands of experiments about which food, beverage, and fragrance ligands interact with various human receptors (olfactory, taste, free fatty acid, TRP, trace-amine-associated receptors etc) and the extent of the activity they cause. 

We have extensive proprietary information about how the ligands cause conformational changes to the affected receptors.